Ai Mediq S.A. is pleased to announce the new stage of scientific cooperation with the Universitätsklinikum Hamburg-Eppendorf (UKE). Together with Dr. Sina Cathérine Rosenkranz we will be looking into potential perspectives of Interval Hypoxic Therapy in the treatment of multiple sclerosis.
Last Friday (26th of July 2019) one of the most recent clinical trials involving ReOxy has been registered with CliniclTrials.gov database with NCT04034082 identifier.
Ai Mediq is pleased to announce approval of new clinical trial named “Evaluation of clinical efficacy of interval hypoxic-hyperoxic trainings in treatment of patients with reduced ejection fraction of left ventricle (2-3 NYHA)
